Abstract

The M₃ subtype of muscarinic acetylcholine receptors (M₃-mAChR) plays a protective role in myocardial ischemia and microRNAs (miRNAs) participate in many cardiac pathophysiological processes, including ischemia-induced cardiac injury. However, the role of miRNAs in M₃-mAChR mediated cardioprotection remains unexplored. The present study was designed to identify miRNAs that are involved in cardioprotective effects of M₃-mAChR against myocardial ischemia and elucidate the underlying mechanisms. We established rat model of myocardial ischemia and performed miRNA microarray analysis to identify miRNAs involved in the cardioprotection of M₃-mAChR. In H9c2 cells, the viability, intracellular free Ca²⁺ concentration ([Ca²⁺]i), intracellular reactive oxygen species (ROS), miR-376b-5p expression level, brain derived neurophic factor (BDNF) and nuclear factor kappa-B (NF-κB) levels were measured. Our results demonstrated that M₃-mAChR protected myocardial ischemia injury. Microarray analysis and qRT-PCR revealed that miR-376b-5p was significantly up-regulated in ischemic heart tissue and the M₃-mAChRs agonist choline reversed its up-regulation. In vitro, miR-376b-5p promoted H₂O₂-induced H9c2 cell injuries measured by cells viability, [Ca²⁺]i and ROS. Western blot and luciferase assay identified BDNF as a direct target of miR-376b-5p. M₃-mAChR activated NF-κB and thereby inhibited miR-376b-5p expression. Our data show that a novel M₃-mAChR/NF-κB/miR-376b-5p/BDNF axis plays an important role in modulating cardioprotection. MiR-376b-5p promotes myocardial ischemia injury possibly by inhibiting BDNF expression and M₃-mAChR provides cardioprotection at least partially mediated by the downregulation of miR-376b-5p through NF-κB. These findings provide new insight into the potential mechanism by which M₃-mAChR provides cardioprotection against myocardial ischemia injury.

Introduction

Ischemic heart disease is the leading cause of death in the industrialized world [1]. Myocardial ischemia could induce unstable angina, arrhythmia, myocardial infarction or its neopathy, leading to sudden cardiac death [2–4]. While many drugs failed to efficaciously treat cardiac death with myocardial ischemia and myocardial infarction [5], recent studies have shown that M₃ subtype of muscarinic acetylcholine receptors (M₃-mAChR) in the heart have cardioprotective effect against myocardial ischemia [6–10].

MicroRNAs (miRNAs) emerge as important regulator of gene expression and have been implicated in numerous cardiovascular pathological processes, including cardiac fibrosis, cardiac hypertrophy, heart failure and cardiac arrhythmia [11–14]. Specially, several miRNAs including miRNA-320 [15], miRNA-21 [16] and miRNA-494 [17] are involved in myocardial ischemia. However, the potential role of miRNAs in cardioprotection of M₃-mAChR remains to be elucidated. Therefore, the present study aimed to explore the contribution of miRNAs to cardioprotective effects mediated by M₃-mAChR against myocardial ischemia. Our results revealed for the first time that miR-376b-5p increased myocardial ischemia injury and was involved in M₃-mAChR’s cardioprotection.

Materials and Methods

Ethics Statement

All experimental protocols were pre-approved by the Experimental Animal Ethic Committee of Harbin Medical University, China (Animal Experimental Ethical Inspection Protocol No. 2009104). Use of animals was confirmed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996).
Reagents

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), trypsin and other tissue culture reagents were obtained from Life Technologies, Inc (Carlsbad, CA, USA). The bicinechonic acid (BCA) protein assay reagents were obtained from Pierce (Rockford, IL, USA). Sodium pentobarbital was obtained from Shanghai Chemicals (Shanghai, China). Choline chloride (choline, agonist of M3-mACHR), 4-diphenylacetoxy-N-methylpyperidine methiodide (4DAMP, antagonist of M3-mACHR) and lipopolysaccharide (LPS, an agonist of NF-κB) were obtained from Sigma (St. Louis, MO, USA). miRNAs were from Shanghai GenePharma Co., Ltd. (Shanghai, China). Lipofectamine 2000 and Alexa Fluor® 800 goat anti-mouse IgG or anti-rabbit IgG were purchased from Invitrogen (Carlsbad, CA, USA). Total RNA Purification Kit was from Norgen Biotek (Thorold, ON, Canada). The mirVanaTM qRT-PCR miRNA Detection Kit was from Ambion (Austin, TX, USA). Bio-Rad Protein Assay Kit was obtained from Bio-Rad (Mississauga, ON, Canada). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was from Roche Diagnostics GmbH (Mannheim, Germany).

Establishment of rat myocardial ischemia model

Male Wistar rats (weight 280–300 g) were randomly divided into four groups: control, ischemia, choline (agonist of M3-mACHR), and choline+4DAMP (antagonist of M3-mACHR) groups. All treatments were administered via the lingual vein with doses of choline and 4DAMP as described previously [7]. Choline (10 mg/kg, i.v.) was administered 10 min before the occlusion. For choline+4DAMP group, 4DAMP (0.12 μg/kg) was administered 5 min before choline. Rat model of myocardial ischemia was established as previously described [8]. Briefly, the rats were anesthetized intraperitoneal injection with sodium pentobarbital (40 mg/kg) and the respiration of rats was controlled by the volume-controlled rodent ventilator. The ventilator setting and the level of anesthesia were adjusted to maintain the animal in an anaesthetic status without spontaneous breathing efforts. A left thoracotomy was performed at the 3rd–4th rib and a segment of saline-soaked 5-0 sutures was looped around the left anterior descending (LAD) coronary artery, near its origin from the left coronary artery. Successful occlusion was observed by electrocardiographic ST-segment elevation. The chest was closed before the rats were weaned from the ventilator and exsanguinated. Rats were put into cage to breed with normal water and feeds after waking up. Mortality rate of the rats were calculated and compared after 24 h myocardial infarction. After 24 h ischemia, rats were reanesthetized and the hearts were removed for the measurement of myocardial infarction. After 24 h ischemia, rats were reanesthetized and the hearts were removed for the measurement of myocardial infarction. After 24 h ischemia, rats were reanesthetized and the hearts were removed for the measurement of myocardial infarction. After 24 h ischemia, rats were reanesthetized and the hearts were removed for the measurement of myocardial infarction.

Measurement of intracellular free Ca2+

H9c2 cells were seeded into 96-well plates at the density of 2×104/well. After 24 h, MiR-376b-5p, miR-376b-5p, 2′-O-methyl-modified antisense oligoribonucleotides of miR-376b-5p (AMO-376b-5p, miR-376b-5p inhibitor) and miR-376b-5p negative control (miR-NC) were synthesized by Shanghai GenePharma. The sequence of AMO-376b-5p was antisense of the mature miRNA sequence (for rat: 5′-GUGGAUAUUCCUCUUCUUAAUGCU-3′) and miR-NC was a random sequence. AMO-376b-5p contained a 2′-O-methyl modification at every base and a 3′C3-containing amino linker.

MTT assay

H9c2 cells were seeded into 96-well plates at the density of 2×104/well. After 24 h, MiR-376b-5p, miR-376b-5p, 2′-O-methyl-modified antisense oligoribonucleotides of miR-376b-5p (AMO-376b-5p, miR-376b-5p inhibitor) and miR-376b-5p negative control (miR-NC) were transfected and incubated for 24 h, followed by treatment with H2O2 (50 μM) for 12 h. Then 10 μl MTT reagents (0.5 mg/ml) was added and incubated for 4 h. After dissolving the formazine granulars with 150 μl dimethyl sulphoxide (DMSO), the absorbance at 570 nm was measured by using a microplate reader. The cell viability = (Acontrol group−Aexperimental group)/Acontrol group×100%.

Measurement of intracellular free Ca2+

H9c2 cells were seeded into 96-well plates at the density of 2×104/well. After 24 h, MiR-376b-5p, miR-376b-5p, 2′-O-methyl-modified antisense oligoribonucleotides of miR-376b-5p (AMO-376b-5p, miR-376b-5p inhibitor) and miR-376b-5p negative control (miR-NC) were transfected and incubated for 24 h, followed by treatment with H2O2 (50 μM) for 12 h. Then 10 μl MTT reagents (0.5 mg/ml) was added and incubated for 4 h. After dissolving the formazine granulars with 150 μl dimethyl sulphoxide (DMSO), the absorbance at 570 nm was measured by using a microplate reader. The cell viability = (Acontrol group−Aexperimental group)/Acontrol group×100%.

MicroRNA microarray analysis

After 24 h ischemia, surrounding tissues of infarcted area from ventricular were departed for microRNA microarray analysis by using hybridization to miRParaloo microfluidics microarrays (LC Sciences) in the version of the Sanger miRBase database Release 10.1 (Release 12, http://mirorna.sanger.ac.uk/). Each detection probe consisted of a chemically modified nucleotide-coding segment complementary to the target miRNA or other target and a spacer segment of polyethylene glycol to extend the coding segment away from the substrate. Each miRNA probe was represented 5 times on a single microarray, and the control probes were spiked into the RNA samples before the labeling. The detection probes were prepared by in situ synthesis using PGR (photogenerated) chemistry to allow highly sensitive and specific detection of miRNAs. The miRParaloo technology enabled on-chip synthesis, ensuring high probe quality and tight process control.

Cell culture

H9c2 myoblast cell line (the rat embryonic ventricular myocardial cell line) were cultured and maintained as monolayer in high glucose DMEM, supplemented with 10% heat inactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin, at 37°C in a humidified incubator with 5% CO2. H9c2 cells were plated at a density of 5000 cells/cm2 and allowed to proliferate in growth medium. Medium was changed every 3 days.

Transfection of miRNAs and miRNA inhibitor

Rat miR-376b-5p, miR-359, 2′-O-methyl-modified antisense oligoribonucleotides of miR-376b-5p (AMO-376b-5p, miR-376b-5p inhibitor) and miR-376b-5p negative control (miR-NC) were synthesized by Shanghai GenePharma. The sequence of AMO-376b-5p was antisense of the mature miRNA sequence (for rat: 5′-GUGGAUAUUCCUCUUCUUAAUGCU-3′) and miR-NC was a random sequence. AMO-376b-5p contained 2′-O-methyl modification at every base and a 3′C3-containing amino linker. H9c2 cells were transfected with miR-NC (100 nM), miR-376b-5p (100 nM), miR-359 (100 nM), miR-376b-5p (100 nM) and AMO-376b-5p (100 nM) using lipofectamine 2000 according to the manufacturer’s instruction and incubated at 37°C for 24 h. Subsequently, cells were maintained in the culture until analysis [11].
AM-loaded cells were detected by laser scanning confocal microscopy (FV-300; Olympus, Tokyo, Japan) at 488 nm excitation and 530 nm emission wavelengths. The acquisition rate was one frame at 10 s intervals and [Ca\(^{2+}\)](i) was monitored for 300 s.

**Measurement of intracellular ROS**

Intracellular reactive oxygen species (ROS) were stained using DCFH-DA. H9c2 cells were seeded into 6-well plates. The cells were treated with \(\text{H}_2\text{O}_2\) (30 \(\mu\)M) for 12 h before transfection with miRNAs. The intracellular ROS levels were measured 24 h after transfection. The cells were washed with serum-free DMEM and incubated with 10 \(\mu\)mol/L DCFH-DA in the loading medium in 5% CO\(_2\)/95% air at 37°C for 20 min. After DCFH-DA was removed, the cells were washed twice and the DCF fluorescence intensity was observed and photographed by laser scanning confocal microscopy (FV-300; Olympus, Tokyo, Japan) at 488 nm excitation and 525 nm emission wavelengths. The acquisition rate was one frame at 10 s intervals and ROS was monitored for 300 s.

**RT-PCR**

Total RNA was isolated from H9c2 cells or rat myocardium with Total RNA Purification Kit. qRT-PCR for miR-376b-5p, miR-539 was performed on a GeneAmp 5700 thermocycler using mirVanaTM miRNA Detection Kit following the manufacturer’s instructions. U6 was used as an internal control. The primers were as follows: U6 primers 5'-GTCGATAGATCTGGCTTCTTGAAG-3' (forward), 5'-GCCCTTCAGGAATTGGGTGTCAGT-3' (reverse), miR-376b-5p primers 5'-GGGGGAGAAATTATCCTT-3' (forward), 5'-GAGCTGGTGTGGTGAGT-3' (reverse), miR-376 primers 5'-GGGGGAGAAATTATCCTT-3' (forward), 5'-TGGCGTGTGCGAT-3' (reverse).

**Western blot analysis**

Whole cell extract and nuclear extract were extracted from H9c2 cells. The protein content was determined with Bio-Rad Protein Assay Kit using bovine serum albumin as the standard. Protein sample (50 \(\mu\)g) was fractionated by 7.5–10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked in 5% milk PBS-Tween20 (PBST) for 3 h and probed with appropriate antibodies: BDNF, NF-kB or GAPDH as internal controls, followed by incubation with Alexa Fluor® 800 goat anti-mouse IgG or anti-rabbit IgG (1:10000) for 1 h. The images were captured on the Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE, USA) and band intensity was quantified using Odyssey v1.2 software.

**Luciferase activity assay**

A fragment of the 3'-untranslated region (3'-UTR) of BDNF containing the putative miR-376b-5p binding sequence was cloned into psiCHECK-2 (Renilla luciferase vector) and the construct (0.5 \(\mu\)g) was transfected into HEK 293T cells with miR-NC, miR-376b-5p, AMO-376b-5p or AMO-376b-5p negative control (AMO-NC). After 24 h, luciferase activities were measured with a dual luciferase reporter assay kit on a luminometer (Lumat LB9507) (EG&G Berthold, Bad Wildbad, Germany).

**Statistical analysis**

Average data were presented as mean ± standard error and were analyzed by analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test. \(P<0.05\) was considered statistically significant.

**Results**

MicroRNAs are involved in M3-mAChR mediated cardioprotection against myocardial ischemia in rat

We established rat model of myocardial ischemia and examined mortality rate and myocardial infarct size. Choline significantly reduced the infarct size, which was reversed by 4DAMP (Figure 1A and B). As expected, choline group showed an obvious decrease in mortality rate (8.33%, \(n = 12\), 1 died) compared to control group subjected to the same procedure (28.6%, \(n = 14\), 4 died), and 4DAMP increased mortality rate (14.3%, \(n = 14\), 2 died) compared to choline group. Taken together, these results confirmed that M3-mAChR provides cardioprotection against myocardial ischemia.

To determine whether miRNAs are involved in M3-mAChR mediated cardioprotection, we performed miRNA microarray analysis and identified 12 differentially upregulated miRNAs upon myocardial ischemia, among which 10 miRNAs were differentially downregulated by M3-mAChR agonist choline (Table 1). While miR-199a, miR-376b-5p, miR-539 and miR-106 were all significantly upregulated (more than 3 times compared to the control), only miR-376b-5p and miR-539 were downregulated to the level similar to the control group after treatment with choline.

To confirm the expression changes of miR-376b-5p and miR-539 in myocardial ischemia, next we performed qRT-PCR analysis and found that miR-376b-5p and miR-539 were significantly upregulated upon myocardial ischemia and downregulated by choline (\(P<0.05\), Figure 1C and D). These data demonstrate that miR-376b-5p and miR-539 are significantly upregulated in ischemic heart of the rats and M3-mAChR agonist choline could reverse their upregulation. Therefore, miR-376b-5p and miR-539 appear to be involved in M3-mAChR mediated cardioprotection against myocardial ischemia.

MiR-376b-5p promotes H\(_2\)O\(_2\) induced H9c2 cells injury

To determine the involvement of miR-376b-5p and miR-539 in myocardial ischemia, we used H9c2 cells as an in vitro model. MTT assay showed that miR-376b-5p significantly enhanced H\(_2\)O\(_2\)-induced inhibition of H9c2 cells viability (\(P<0.05\), which was reversed by AMO-376b-5p. However, miR-539 had no significant effect on H\(_2\)O\(_2\)-induced inhibition of H9c2 cells viability (Figure 2A). These results suggest that miR-539 is unlikely involved in myocardial ischemia and we focused on miR-376b-5p in the following experiments.

The overload of intracellular free Ca\(^{2+}\) concentration ([Ca\(^{2+}\)](i)) is an important cause of cell injury [7,9]. Therefore, we examined [Ca\(^{2+}\)](i) in H\(_2\)O\(_2\)-treated H9c2 cells and found that miR-376b-5p significantly increased the overload of [Ca\(^{2+}\)](i) (\(P<0.05\)) while AMO-376b-5p reversed this increase (Figure 2B).

Moreover, miR-376b-5p significantly increased the intracellular ROS in H\(_2\)O\(_2\)-treated H9c2 cells (\(P<0.05\)) and this effect was reversed by AMO-376b-5p (Figure 2C). Taken together, these results suggest that miR-376b-5p promotes H\(_2\)O\(_2\)-induced H9c2 cells injury.

M3-mAChR inhibits H\(_2\)O\(_2\) induced upregulation of miR-376b-5p in H9c2 cells

To examine further miR-376b-5p expression in ischemic myocardial cells and the effects of M3-mAChR on miR-376b-5p expression in vitro, H9c2 cells were co-incubated with H\(_2\)O\(_2\) (50 \(\mu\)M), choline (1 mM) or 4DAMP (5 nM) for 12 h. The results showed that H\(_2\)O\(_2\) significantly upregulated the miR-376b-5p expression.
expression ($P<0.01$) and this effect was antagonized by M3-mAChR agonist choline (Figure 3). Furthermore, M3-mAChR antagonist 4DAMP reversed the effect of choline on miR-376b-5p. These results are consistent with the results of gene array analysis verified by qRT-PCR (Figure 1C) and suggest that M3-mAChR inhibits the up-regulation of miR-376b-5p stimulated by H2O2 in H9c2 cells.

BDNF is a target gene of miR-376b-5p in cardiac myocytes

To further explore the role of miR-376b-5p in myocardial ischemia, we predicted the targets of miR-376b-5p by targetScan Release 5.1 online (www.targetscan.org) and focused on BDNF (Figure 4A). Next we determined the expression of BDNF at the protein level in H9c2 cells and found that miR-376b-5p significantly reduced the expression of BDNF ($P<0.05$), and this reduction was reversed by AMO-376b-5p (Figure 4B). These results suggest that BDNF is a target gene of miR-376b-5p.

To confirm that miR-376b-5p could directly bind to BDNF gene and inhibit its expression, a reporter construct with the insertion of a fragment of the 3’-UTR of BDNF mRNA containing the predicted miR-376b-5p binding site was transfected into HEK 293T cells. Luciferase assay showed that miR-376b-5p significantly reduced the luciferase activity ($P<0.05$) while AMO-376b-5p significantly increased the luciferase activity ($P<0.05$) (Figure 4C). Taken together, these data prove that miR-376b-5p directly inhibits BDNF expression.

Table 1. The levels of differentially expressed miRNAs in the rat suffered from myocardial ischemia or administrated with choline after ischemia.

| Probe_ID | Control | Ischemia | Ischemia-choline |
|----------|---------|----------|-----------------|
| rno-miR-199a | 1 | 12.7 | 2.30 |
| rno-miR-449 | 1 | 1.80 | 1.20 |
| rno-miR-376b-5p | 1 | 9.70 | 1.87 |
| rno-miR-539 | 1 | 4.00 | 0.81 |
| rno-miR-106 | 1 | 3.15 | 0.15 |
| rno-miR-92 | 1 | 2.52 | 1.11 |
| rno-miR-135b | 1 | 1.80 | 1.16 |
| rno-miR-349 | 1 | 1.58 | 0.41 |
| rno-miR-122a | 1 | 1.65 | 1.10 |
| rno-miR-18 | 1 | 2.00 | 1.03 |

Male Wistar rats were divided into control, ischemia and choline chloride (choline, agonist of M3-mAChR) groups. Myocardial ischemia model was induced for 24 h. Choline (10 mg/kg, i.v.) was administrated 10 min before occlusion. After 24 h ischemia, ventricular tissues were dissected for miRNA microarray analysis. MiRNAs levels were calculated based on the normalization to control group (set as 1).

doi:10.1371/journal.pone.0032571.t001
NF-κB mediates the inhibitory effect of M₃-mAChR on miR-376b-5p expression in H9c2 cells

Previous studies demonstrated that M₃-mAChR could activate NF-κB [18–20]. Moreover, 3 binding sites of NF-κB were predicted on the promoter of miR-376b-5p gene by TFSEARCH (Figure 5A). Therefore, we postulated that NF-κB possibly mediates the inhibitory effects of M₃-mAChR on miR-376b-5p expression.

To verify that M₃-mAChR could activate NF-κB, we determined nuclear NF-κB protein level in H9c2 cells. Western blot analysis showed that nuclear NF-κB level was significantly increased (p < 0.05, Figure 5B) after treatment with choline with no significant variance of total NF-κB level, suggesting that M₃-mAChR could activate NF-κB.

Next we measured miR-376b-5p expression by qRT-PCR in H9c2 cells treated with LPS (100 ng/ml), which is known to activate NF-κB in many previous studies [21–23]. As expected, LPS significantly activated NF-κB (p < 0.05, Figure 5C) with no significant variance of total NF-κB level. Furthermore, LPS significantly reduced miR-376b-5p expression (p < 0.05, Figure 5D). Collectively, these data indicate that NF-κB mediates the inhibitory effect of M₃-mAChR on miR-376b-5p expression.

Discussion

In the present study, for the first time, we found that miR-376b-5p inhibited the expression of BDNF and miR-376b-5p promoted H₂O₂-induced H9c2 cells injury, indicating that miR-376b-5p promoted myocardial ischemia injury possibly by inhibiting the expression of BDNF. Moreover, we found that M₃-mAChR inhibited miR-376b-5p expression by activating NF-κB. These findings provide new insight into the potential mechanism of cardioprotection of M₃-mAChR against myocardial ischemia.

First, we observed that M₃-mAChR decreased infarct size and mortality rate in rat models, consistent with previous studies showing that M₃-mAChR has the protective effect against myocardial ischemia [6–10]. Next, to explore the underlying mechanisms responsible for our observation, we focused on miRNAs, given their emerging role in the pathogenesis of the cardiovascular system including myocardial ischemia [11–17]. Based on microarray analysis and further validation by qRT-PCR, we postulated that the upregulation of miR-376b-5p and miR-539 is involved in myocardial ischemia and M₃-mAChR may protect against myocardial ischemia via the downregulation of miR-376b-5p and miR-539 expression.

H9c2 cells were treated with H₂O₂ for 12 h to simulate myocardial ischemia injury, which was employed as in vitro model.
(A) MiR-376b-5p binding site in 3'-untranslated region (3'-UTR) of BDNF gene. (B) Inhibitory effects of miR-376b-5p on BDNF expression at the protein level. BDNF level was determined by Western blot after H9c2 cells were transfected with miR-376b-5p negative control (miR-NC), miR-376b-5p and 2'-O-methyl-modified antisense oligoribonucleotides of miR-376b-5p (AMO-376b-5p, miR-376b-5p inhibitor) for 24 h. GAPDH served as loading control. Top, representative Western blots; bottom, quantitation as mean ± SEM. Note: n = 3; *P<0.05 vs. miR-NC, #P<0.05 vs. miR-376b-5p. (C) Luciferase assay for direct inhibitory effects of miR-376b-5p on BDNF expression. The reporter construct was transfected into HEK 293T cells with miR-NC, miR-376b-5p, AMO-376b-5p or AMO-376b-5p negative control (AMO-NC). Luciferase activity was normalized by Firefly luciferase signal in HEK 293T cells. Following transfection for 24 h, luciferase activities were measured on a luminometer. Values were expressed as mean ± SEM; n = 3; *P<0.05 vs. miR-NC, #P<0.05 vs. AMO-NC.

doi:10.1371/journal.pone.0032571.g004

MiR-376b is Involved in M3-R’s Cardioprotection
Supporting Information

Figure S1 MiRNA transfection efficiency. (A) Representative H9c2 cell photomicrographs transfected with miRNA with fluorescence. (B) MiR-376b-5p level was significantly up-regulated after transfection with miR-376b-5p. H9c2 cells were transfected with miR-376b-5p for 24 h. MiR-376b-5p level was determined by quantitative real-time RT-PCR (qRT-PCR). Note: Values are expressed as mean ± SEM; n = 3 independent experiments; *P<0.05 versus Control.

Author Contributions
Conceived and designed the experiments: YL ZD. Performed the experiments: ZP KF HZ YF JX FG YG HQ YH SW YZ NW RH. Analyzed the data: ZP YH YG YL. Wrote the paper: ZP YG YL.

References
1. Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418–458.
2. Boli R, Fisher DJ, Taylor AA, Young JB, Miller RR (1984) Effect of alpha-adrenergic blockade on arrhythmias induced by acute myocardial ischemia and reperfusion in the dog J Mol Cell Cardiol 16: 1101–1117.
3. Myerburg RJ, Kessler KM, Castellanos A (1993) Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 119: 1187–1197.
4. Ferreira M, Santos-Silva PR, de Almeida LC, Valenti VE, Crispim V, et al. (2010) Sudden cardiac death athletes: a systematic review. Sports Med Arthrosc Rehabil Ther Technol 2: 19.
5. Downey JM, Cohen MV (2009) Why do we still not have cardioprotective drugs? Circulation 73: 1171–1177.
6. Shi H, Wang H, Wang Z (1999) Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Mol Pharmacol 55: 497–507.
7. Yang B, Lin H, Xu C, Liu Y, Wang H, et al. (2005) Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac M3 subtype muscarinic acetylcholine receptors. Cell Physiol Biochem 16: 163–174.
8. Yue P, Zhang Y, Du Z, Xiao J, Pan Z, et al. (2006) Ischemia impairs the association between connexin 43 and M3 subtype of acetylcholine muscarinic receptor (M3mAChR) in ventricular myocytes. Cell Physiol Biochem 17: 129–136.
9. Liu Y, Sun HL, Li DL, Wang LY, Gao Y, et al. (2008) Choline produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of intracellular Ca2+ handling as a common mechanism. Can J Physiol Pharmacol 86: 860–865.
10. Liu Y, Du J, Gao Y, Zhang Y, Cai BZ, et al. (2009) Role of M3 receptor in aconitine/barium-chloride-induced preconditioning against arrhythmias in rats. Naunyn Schmiedebergs Arch Pharmacol 379: 511–515.
11. Yang B, Lin H, Xiao J, Lu Y, Luo X, et al. (2007) The muscle-specific microRNAmiR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491.
12. Li Q, Song XW, Zhou J, Wang GK, Kremenova E, et al. (2010) Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twist1-1 to provoke cardiac hypertrophy. J Cell Sci 123: 2444–2452.
13. Kumaraswamy R, Anker SD, Thum T (2010) MicroRNAs as circulating biomarkers for heart failure: questions about MiR-423-5p. Circ Res 106: e8.

14. Matkovich SJ, Wang W, Tu Y, Eschenhacker WH, Dorn LE, et al. (2010) MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106: 166-175.

15. Ren XP, Wu J, Wang X, Sartor MA, Qian J, et al. (2009) MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat Shock Protein 20. Circulation 119: 431–439.

16. Cheng Y, Zha P, Yang J, Liu X, Dong S, et al. (2010) Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDK3/D4. Cardiovasc Res 87: 431–439.

17. Wang X, Zhang X, Ren XP, Chen J, Liu H, et al. (2010) MicroRNA-494 Targeting Both Proapoptotic and Antiapoptotic Proteins Protects Against Ischemia/Reperfusion-Induced Cardiac Injury. Circulation: 122: 1308-1318.

18. Fujino H, Uehara T, Murayama T, Okuma Y, Ariga H, et al. (2000) Extracellular signal regulated protein kinase and c-jun N-terminal kinase are involved in ml muscarinic receptor-enhanced interleukin-2 production pathway in Jurkat cells. J Biol Pharm Bull 23: 1198–1205.

19. Siehl S, Wang Y, Fan X, Windfueh RT, Manning DR (2001) Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J Biol Chem 276: 40733–40739.

20. Zheng H, Chen D, Zhang J, Tian Y (2004) Involvement of M1 cholinergic-receptor signal transduction pathway in regulation of the expression of chemokine MOB-1, MCP-1 genes in pancreatic acinar cells. J Huazhong Univ Sci Technolog Med Sci 24: 140–145, 157.

21. Valen G, Yan ZQ, Hansson GK (2001) Nuclear factor kappa B and the heart. J Am Coll Cardiol 38: 307–314.

22. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB plays an essential role in the late phase of ischemic preconditioning in rats. Proc Natl Acad Sci USA 103: 12481–12486.

23. Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, et al. (2009) Induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103: 12481–12486.

24. Akanji AO, Suresh CG, Al-Radwan R, Fatania HR (2007) Insulin-like growth factor 1, AP-1, and NFkappaB on cardiomyocyte apoptosis during myocardial ischaemia-reperfusion injury. Basic Res Cardiol 92: 201–213.

25. Lopting CM, Pascual JR, Palacios CI, et al. (2000) Cardiomyocytes hypertrophy status after myocardial infarction determines distinct types of arrhythmia: role of the ryanodine receptor. Prog Biophys Mol Biol 103: 71–80.

26. Guo ZY, Jiao Q, Wang ST, Xu MH, Gao FH (2008) Effect of ryanodine receptor 2 gene silencing on ischemia-reperfusion injury of rat myocardial cells. Zhonghua Bing Li Xue Za Zhi 37: 760–764.

27. Guo Z, Wang S, Jiao Q, Xu M, Gao F (2010) RNAi targeting ryanodine receptor 2 protects rat cardiomyocytes from injury caused by simulated ischemia-reperfusion. Biomed Pharmacother 64: 184–190.

28. Fauconnier J, Paquin J, Bieleux P, Lacampagne A, Richard S (2010) Cardiomyocytes hypertrophic status after myocardial infarction determines distinct types of arrhythmia: role of the ryanodine receptor. Prog Biophys Mol Biol 103: 71–80.

29. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, et al. (1997) Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. The Annals of thoracic surgery 64: 993–998.

30. Donovan MJ, Lin MI, Wieg P, Ringstedt T, Kraemer R, et al. (2000) Brain-derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127: 4531–4540.

31. Hiltunen JO, Laurikainen A, Vakeva A, Meri S, Saarma M (2001) Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischemia and reperfusion. J Pathol 194: 247–253.

32. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, et al. (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer research 66: 4249–4253.

33. Kreusser MM, Buss SJ, Krebs J, Kirschner R, Metz J, et al. (2008) Differential expression of cardiac neurotrophic factors and sympathetics nerve ending abnormalities within the failing heart. J Mol Cell Cardiol 44: 330–337.

34. Lorgis L, Amourottes S, Vergely C, Zeller M, Gotin Y, et al. (2009) Brain-derived neurotrophic factor (BDNF): role of this neurotrophin in cardiovascular physiopathology. Ann Cardiol Angeiol 50: 99–103.

35. Katsu RE, Kakinuma Y, Arakawa M, Yamasaki F, Sato T (2009) Chronic intermittent fasting improves the survival following large myocardial ischemia by activation of BDNF/VEGF/PI3K signaling pathway. J Mol Cell Cardiol 46: 405–412.

36. Maulik N, Sato M, Price BD, Das DK (1998) An essential role of NFkappB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischaemia. FEBS Lett 429: 365–369.

37. Maulik N, Groswami S, Galang N, Das DK (1999) Differential regulation of Bel-2, AP-1, and NFkappB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation. FEBS Lett 443: 331–336.

38. Dana A, Jonasen AK, Yamashita N, Yellon DM (2000) Adenosine A1 receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 101: 2041–2048.

39. Gunina RJ, Newman PJ, Kenny D, Warlter DC, Gross GJ (1997) The eukaryote cell adhesion cascade and its role in myocardial ischaemia-reperfusion injury. Basic Res Cardiol 92: 201–213.

40. Shirama N, Yoshiyama M, Oomura T, Hanatani A, Kim S, et al. (1998) Activation of mitogen-acted protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116–124.

41. Gain BS, Harken AH, Moldrum DR (1999) Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. J Mol Cell Cardiol 31: 941–947.

42. Ono K, Matsumori A, Furukawa Y, Iigata H, Shioi T, et al. (1999) Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemotactic protein-1. Lab Invest 79: 195–203.

43. Morgan EN, Boyle EM, Yun W, Griscavage-Ennis JM, Farr AL, et al. (1999) An essential role for NFkappB in the cardioprotective response to ischemia. Ann Thorac Surg 68: 377–382.

44. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, et al. (1999) Nuclear factor-kappa B plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84: 1093–1100.

45. Todisco A, Ramamoorthy S, Pausawasdi N, Tacey K (1999) Carbachol activates KappaB kinase in isolated canine gastric parietal cells. J Biochem Biophys Res Commun 261: 877–884.